Literature DB >> 16510278

Inflammatory chemokines in cancer growth and progression.

Barrett J Rollins1.   

Abstract

Leukocyte infiltration is a cardinal feature of almost all cancers. Chemokines are generally responsible for eliciting local accumulation of inflammatory cells and they appear to play the same role in the formation of peri- and intra-tumoural infiltrates. Chronic inflammation predisposes to cancer formation and progression, and it is likely that the chemokine system contributes to this process. In part, this may be a consequence of its ability to attract mononuclear cells to cancer sites, where they provide growth or angiogenic factors that enhance cancer development. However, accumulating evidence also points to a direct effect of chemokines on cancer cells that express chemokine receptors. In particular, some chemokines can activate anti-apoptotic pathways in these cells. By either mechanism, tumour cells that secrete and/or respond to chemokines would have a selective advantage. This provides another example of cancer's ability to co-opt host systems in order to promote tumour progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510278     DOI: 10.1016/j.ejca.2006.01.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  69 in total

1.  Association of progressive structural changes in the bronchial epithelium with subepithelial fibrous remodeling: a potential role for hypoxia.

Authors:  Vasiliy V Polosukhin; William E Lawson; Aaron P Milstone; Svetlana M Egunova; Andrey G Kulipanov; Sergey G Tchuvakin; Pierre P Massion; Timothy S Blackwell
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

Review 2.  Bioactive dietary long-chain fatty acids: emerging mechanisms of action.

Authors:  Robert S Chapkin; David N McMurray; Laurie A Davidson; Bhimanagouda S Patil; Yang-Yi Fan; Joanne R Lupton
Journal:  Br J Nutr       Date:  2008-05-20       Impact factor: 3.718

3.  The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma.

Authors:  Juliana Romanini; Tânia R Mielcke; Paulo C Leal; Cláudia P Figueiredo; João B Calixto; Fernanda B Morrone; Eraldo L Batista; Maria M Campos
Journal:  Invest New Drugs       Date:  2011-06-14       Impact factor: 3.850

4.  Polymorphisms of Toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility.

Authors:  Qiong Dai; Xing Pu Li; Li Chai; Han An Long; Zhi Hui Yang
Journal:  Tumour Biol       Date:  2014-02-07

5.  Regulation of deoxycholate induction of CXCL8 by the adenomatous polyposis coli gene in colorectal cancer.

Authors:  Nathaniel S Rial; Gwendal Lazennec; Anil R Prasad; Robert S Krouse; Peter Lance; Eugene W Gerner
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

Review 6.  Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner.

Authors:  Thomas Dittmar; Christoph Heyder; Eva Gloria-Maercker; Wolfgang Hatzmann; Kurt S Zänker
Journal:  Clin Exp Metastasis       Date:  2007-09-08       Impact factor: 5.150

Review 7.  The tumor microenvironment and its contribution to tumor evolution toward metastasis.

Authors:  Girieca Lorusso; Curzio Rüegg
Journal:  Histochem Cell Biol       Date:  2008-11-06       Impact factor: 4.304

Review 8.  Tumor vaccines for breast cancer.

Authors:  Karen S Anderson
Journal:  Cancer Invest       Date:  2009-05       Impact factor: 2.176

9.  Role of eotaxin-1 signaling in ovarian cancer.

Authors:  Vera Levina; Brian M Nolen; Adele M Marrangoni; Peng Cheng; Jeffrey R Marks; Miroslaw J Szczepanski; Marta E Szajnik; Elieser Gorelik; Anna E Lokshin
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

10.  The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers.

Authors:  Merav Darash-Yahana; John W Gillespie; Stephen M Hewitt; Yun-Yun K Chen; Shin Maeda; Ilan Stein; Satya P Singh; Roble B Bedolla; Amnon Peled; Dean A Troyer; Eli Pikarsky; Michael Karin; Joshua M Farber
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.